The marginal kidney donor

Current Opinion in Urology

Volumn 12, Issue 2, 2002, Pages 101-107

  Tullius, Stefan G ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RAPAMYCIN; STEROID;

AGE; BRAIN DEATH; CAUSE OF DEATH; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY MASS; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM; STEROID THERAPY;

HUMANS; KIDNEY TRANSPLANTATION; RISK FACTORS; TISSUE DONORS; TRANSPLANTS;

EID: 0036178390     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200203000-00004     Document Type: Review

References (66)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Antigen-independent determinants of cadaveric kidney transplant failure
3. Risk factors for renal allograft survival from older cadaver donors
4. Five-year follow-up of 250 recipients of cadaveric kidney allografts from donors older than 55 years of age
5. Nephron underdosing: A programmed cause of chronic renal allograft failure
6. Utilization of the older donor for renal transplantation
7. Double versus single renal allografts from aged donors
8. Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal allografts
9. A review of the kidneys that nobody wanted: Determinants of optimal outcome
10. Pre-transplant hypertension: A major risk factor for chronic progressive renal allograft dysfunction
11. Evaluation of the older cadaveric kidney donor: The impact of donor hypertension and creatinine clearance on graft performance and survival
12. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study
13. Improvement of kidney transplant results by using trauma death donors
14. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK
15. Brain death and its influence on donor organ quality and outcome after transplantation
16. Activation of inflammatory mediators in rat renal isografts by donor brain death
17. Accelerated rejection of renal allografts from brain dead donors
18. Long-term kidney isografts develop functional and morphological changes that mimic those of chronic allograft rejection
19. The contribution of reduced functioning mass to chronic kidney allograft dysfunction in rats
20. Molecular analyses of human renal allografts: Differential intragraft gene expression during rejection
21. A molecular injury-response model for the understanding of chronic disease
22. Donor catecholamine use reduces acute allograff rejection and improves graft survival after cadaveric renal transplantation
23. Ischemia/reperfusion iniury in transplantation
24. Deleterious effects of delayed graft function in cadaveric transplant recipients independent of acute rejection
25. Delayed graft function after renal transplantation
26. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys
27. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation
28. The incidence and impact of early rejection, episodes on graft outcome in recipients of first cadaver transplants
29. Predictors of renal transplant histology at three months
30. Contribution of prolonged ischemia and donor age to chronic renal allograft
31. Does the immunogenicity of cadaver donor kidneys influence early posttransplant events?
32. The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction
33. Delayed graft function: State of the art. November 10-11, Summit Meeting, Scottsdale, Arizona, USA
34. Significance of the donor age effect on kidney transplants
35. Double versus single renal allografts from aged donors
36. Early experience with dual kidney transplantation in adults expanding donor criteria
37. Cadaveric 'two-in-one' kidney transplantation from marginal donors: Experience of 26 cases after 3 years
38. Outcome in recipients of dual kidney transplants
39. Examination of hemodynamic, endocrinological and inflammatory parameters in organ donors under the influence of methylprednisolone
40. Donor-pretreatment of grafts from marginal donors improves long-term graft outcome
41. Donor treatment with mycophenolate mofetil: Protection against ischemia-reperfusion injury in the rat
42. Heme oxygenase: Protective gene or trojan horse
43. Antibody induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes
44. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury
45. Induction of hemeoxygenase-1 prevents ischemia/reperfusion injury and improves long-term graft outcome in rat renal allografts
46. Improvement of long-term function in renal allografts from 'marginal donors' following the induction of heme-oxygenase-1
47. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
48. Effects of RS 61443 on functional and morphological changes in chronically rejecting rat kidney allografts
49. Transplantation in the elderly: A review
50. Age-matching in renal transplantation
51. Optimal use for older donor kidneys: Older recipients
52. Relationship of recipient and age and the development of chronic allograft failure
53. Renal transplantation in older adults: Is graft survival affected by age? A case control study
54. Renal transplantation in recipients over the age of 60: The impact of donor age
55. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a sub-optimal graft
56. Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors
57. 'Suboptimal' kidney donors: The experience with tacrolimus-based immnosuppression
58. Risk factors for chronic rejection in renal allograft recipients
59. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
60. The aging immune system: Primer and prospectus
61. Influence of recipient and donor age on long-term renal allograft function in an experimental model
62. Recipient age and weight affect chronic renal allograft rejection in rats
63. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates
64. Preservation of kidneys from marginal donors with pulsatile perfusion machine
65. Pretransplant evaluation of renal viability by glutathione S-transferase in machine pertusion